Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

2019 Annual Meeting of Stockholders

Jun 13, 2019 • 10:00am EDT